Last reviewed · How we verify
CAR
CAR is a combination antiretroviral therapy containing cabotegravir and rilpivirine that suppresses HIV replication by inhibiting integrase and reverse transcriptase.
CAR is a combination antiretroviral therapy containing cabotegravir and rilpivirine that suppresses HIV replication by inhibiting integrase and reverse transcriptase. Used for HIV-1 infection in treatment-naive and treatment-experienced adults (as Cabenuva long-acting injectable formulation).
At a glance
| Generic name | CAR |
|---|---|
| Also known as | CAR-T cell therapy |
| Sponsor | ViiV Healthcare |
| Drug class | Antiretroviral combination therapy (INSTI + NNRTI) |
| Target | HIV integrase and HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Cabotegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV from integrating its genetic material into host cell DNA. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the enzyme responsible for converting HIV RNA into DNA. Together, these agents provide dual-mechanism suppression of viral replication.
Approved indications
- HIV-1 infection in treatment-naive and treatment-experienced adults (as Cabenuva long-acting injectable formulation)
Common side effects
- Injection site reactions
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN） (PHASE1)
- Descartes-08 for Patients With Systemic Lupus Erythematosus (PHASE2)
- A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (PHASE1)
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (PHASE1, PHASE2)
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy (PHASE2, PHASE3)
- Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAR CI brief — competitive landscape report
- CAR updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI